Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, vol.6, no.1, pp.33-38, 2016 (SCI-Expanded)
- Publication Type: Article / Article
- Volume: 6 Issue: 1
- Publication Date: 2016
- Doi Number: 10.1177/2045125315624063
- Journal Name: THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
- Page Numbers: pp.33-38
- Keywords: clozapine, leukopenia, lithium, neutropenia, treatment-resistant, schizophrenia, INDUCED AGRANULOCYTOSIS, RESISTANT SCHIZOPHRENIA, BLOOD DYSCRASIAS, SAFETY, TRIAL, RECHALLENGE, PREVENTION, THERAPY
- Süleyman Demirel University Affiliated: No
Abstract
Objective: Clozapine is a second-generation antipsychotic used for treatment-resistant schizophrenia. Despite its effectiveness, clozapine is largely underused due to serious side effects such as leukopenia or neutropenia. We aimed to review whether to continue, discontinue or rechallenge clozapine treatment after such haematological side effects.